FDA Licenses Merck’s Capvaxive Pneumococcal Vaccine
On June 17, 2024, the U.S. Food and Drug Administration (FDA) licensed Merck & Company, Inc.’s new pneumococcal conjugate vaccine Capvaxive (formerly V116) for adults 18 years of age and older. The vaccine is designed to protect against 21 types of the bacteria causing pneumococcal disease, which can lead to severe infection in the lungs […]
Inside Big Pharma: The Dark Side of Pharmaceutical Giants
In a career spanning more than twenty years, Bernard Dalbergue has learned everything there is to know about pharmaceutical laboratories. At the beginning of 2011, he decided to quit this world, with its practices and its lies. Above all, he decided to reveal to us everything he knew about his employer: the international drug company […]
Merck Sued Again for Gardasil Vaccine Adverse Events
The number of lawsuits filed in North Carolina against Merck for its HPV (human papillomavirus) vaccine, Gardasil, continue to mount and allege the company did not prove the vaccine was safe and effective before marketing it as an anti-cancer vaccine. Since 2022, almost 200 lawsuits alleging serious injury after receiving Gardasil have been consolidated in […]
FDA Adds Boxed Warning to Merck’s Asthma Drug Singulair About Suicide, Neuropsychiatric Side Effects
In 2008, the FDA issued a warning advising that it would investigate a possible risk of suicide associated with Merck & Co.’s asthma and allergy drug Singulair after there were many reports of increases in agitation, aggression, anxiety, depression and suicidal thoughts. Hallucinations also were documented for children and adolescents taking Singulair. When the drug’s […]
Only 14 Percent of American Adults Have Received Updated COVID Booster Shots
Only 13.9 percent of the U.S. adult population have rolled up their sleeves for the updated COVID-19 shot, according to the U.S. Centers for Disease Control and Prevention (CDC). The mRNA monovalent COVID booster shot, approved by the U.S. Food and Drug Administration (FDA) on Sept. 11, 2023 despite only being tested on mice, was […]
One in Five Paxlovid Users Experience COVID Rebound Infections
A new study published earlier this month suggests that people who took Pfizer’s Paxlovid (nirmatrelvir-ritonavir)—an antiviral drug treatment for COVID-19—are much more likely to experience reinfection than those who did not take the drug. The study, published in the Annals of Internal Medicine, reported that one in five people who take Paxlovid could experience rebound […]